158 related articles for article (PubMed ID: 17803678)
21. [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
Kyrcz-Krzemień S; Helbig G; Stella-Hołowiecka B; Hołowiecki J
Wiad Lek; 2003; 56(5-6):227-32. PubMed ID: 14526479
[TBL] [Abstract][Full Text] [Related]
22. Thromboembolism in patients on thalidomide for myeloma.
Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
[TBL] [Abstract][Full Text] [Related]
23. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
25. [Single-agent thalidomide for advanced and refractory multiple myeloma].
Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
27. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
Thomson KF; Goodfield MJ
J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
[TBL] [Abstract][Full Text] [Related]
28. Advantages of using thalidomide for the management of refractory myeloma patients.
Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M
Haematologica; 2002 Mar; 87(3):327-8. PubMed ID: 11869949
[TBL] [Abstract][Full Text] [Related]
29. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
[TBL] [Abstract][Full Text] [Related]
31. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
[TBL] [Abstract][Full Text] [Related]
32. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.
Bernardeschi P; Giustarini G; Montenora I; Turrisi G; Dentico P; Rossi S; Turano E; Fiorentini G
In Vivo; 2006; 20(6A):719-20. PubMed ID: 17203753
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
35. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
36. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
37. Thalidomide in the treatment of multiple myeloma.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
39. Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide therapy and polyneuropathy in myeloma patients.
Laaksonen S; Remes K; Koskela K; Voipio-Pulkki LM; Falck B
Electromyogr Clin Neurophysiol; 2005 Mar; 45(2):75-86. PubMed ID: 15861857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]